SNCA and Parkinson disease: Withanolide A also showed proteopathies effects by decreasing α-synuclein levels 38% in of NL5901 Caenorhabditis elegans, a Parkinson's disease model, suggesting beneficial effects of withanolide A for PD patients (Akhoon et al., 2016).